Review of Oxygenation with Nanobubbles: Possible Treatment for Hypoxic COVID-19 Patients
Source abstract
Abstract
The coronavirus disease (COVID-19) pandemic, which has spread around the world, caused the death of many affected patients, partly because of the lack of oxygen arising from impaired respiration or blood circulation. Thus, maintaining an appropriate level of oxygen in the patients' blood by devising alternatives to ventilator systems is a top priority goal for clinicians. The present review highlights the ever-increasing application of nanobubbles (NBs), miniature gaseous vesicles, for the oxygenation of hypoxic patients. Oxygen-containing NBs can exert a range of beneficial physiologic and pharmacologic effects that include tissue oxygenation, as well as tissue repair mechanisms, antiinflammatory properties, and antibacterial activity. In this review, we provide a comprehensive survey of the application of oxygen-containing NBs, with a primary focus on the development of intravenous platforms. The multimodal functions of oxygen-carrying NBs, including antimicrobial, antiinflammatory, drug carrying, and the promotion of wound healing are discussed, including the benefits and challenges of using NBs as a treatment for patients with acute hypoxemic respiratory failure, particularly due to COVID-19.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Cardiovascular and Diving-Related Complications · Nanoplatforms for cancer theranostics · Cerebrospinal fluid and hydrocephalus
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Physics, Sharif University of Technology, P.O. Box 11155-9161, Tehran 14588-89694, Iran
Laser Research Centre, Faculty of Health Science, University of Johannesburg, Doornfontein 2028, South Africa
Regional Center of Advanced Technologies and Materials, Czech Advanced Technology and Research Institute, Palacky University, Šlechtitelů 27, Olomouc 78371, Czech Republic
Funding
National Institute of Allergy and Infectious Diseases
References (100+)
Show source-provided references
1. 10.1016/S0140-6736(20)30937-510.1016/S0140-6736(20)30937-5 ↗
2. Razorenova O. V. · 2010 · 4310.1007/978-1-4419-6615-5_3 ↗
3. 10.1007/s11033-021-06358-110.1007/s11033-021-06358-1 ↗
4. 10.4045/tidsskr.20.029910.4045/tidsskr.20.0299 ↗
5. 10.1038/s42255-020-0237-210.1038/s42255-020-0237-2 ↗
6. 10.1158/0008-5472.CAN-09-271510.1158/0008-5472.CAN-09-2715 ↗
7. 10.1001/jama.2020.1283910.1001/jama.2020.12839 ↗
8. 10.1186/s40635-016-0108-z10.1186/s40635-016-0108-z ↗
9. Kondo A. · Cancer Res. · 2001 · 61 · 7603
10. 10.1186/2041-9414-4-510.1186/2041-9414-4-5 ↗
11. 10.1001/jama.2020.504610.1001/jama.2020.5046 ↗
12. Abdelsalam M. · Respir. Care · 2010 · 55 · 1483
13. 10.1001/jama.2020.961110.1001/jama.2020.9611 ↗
14. 10.1021/la000219r10.1021/la000219r ↗
15. 10.1016/j.ultras.2003.11.01110.1016/j.ultras.2003.11.011 ↗
16. 10.1016/j.eti.2021.10172910.1016/j.eti.2021.101729 ↗
17. 10.1103/PhysRevFluids.3.11050410.1103/PhysRevFluids.3.110504 ↗
18. 10.1039/C9CS00839J10.1039/C9CS00839J ↗
19. 10.1111/iwj.1287310.1111/iwj.12873 ↗
20. 10.1021/acs.est.9b0282110.1021/acs.est.9b02821 ↗
21. 10.1093/cid/ciaa53010.1093/cid/ciaa530 ↗
22. 10.1128/EC.00350-0810.1128/EC.00350-08 ↗
23. 10.1021/acsami.0c0702210.1021/acsami.0c07022 ↗
24. Klopfer M. J. · 2015
25. 10.1186/s12967-020-02364-210.1186/s12967-020-02364-2 ↗
26. 10.1021/acsnano.0c0400610.1021/acsnano.0c04006 ↗
27. 10.1021/nn300261t10.1021/nn300261t ↗
28. 10.1039/C7TB01689A10.1039/C7TB01689A ↗
29. 10.1021/nn101390x10.1021/nn101390x ↗
30. 10.1021/cr300335p10.1021/cr300335p ↗
31. 10.1039/b716534j10.1039/b716534j ↗
32. 10.1021/acsbiomaterials.8b0065810.1021/acsbiomaterials.8b00658 ↗
33. 10.1039/C9GC01759C10.1039/C9GC01759C ↗
34. 10.3390/nano1006107210.3390/nano10061072 ↗
35. 10.3390/ijms2114512610.3390/ijms21145126 ↗
36. 10.3390/app1010364110.3390/app10103641 ↗
37. 10.1016/j.nantod.2020.10096210.1016/j.nantod.2020.100962 ↗
38. 10.1021/acsnano.0c0369710.1021/acsnano.0c03697 ↗
39. Oxygen Sources and Distribution for COVID-19 Treatment Centres: Interim Guidance, 4 April 2020; World Health Organization, 2020.
40. 10.1016/j.ultrasmedbio.2017.08.188310.1016/j.ultrasmedbio.2017.08.1883 ↗
41. 10.1038/nrc318310.1038/nrc3183 ↗
42. 10.1016/j.pharmthera.2016.04.00910.1016/j.pharmthera.2016.04.009 ↗
43. 10.1007/s00018-008-7472-010.1007/s00018-008-7472-0 ↗
44. Ziello J. E. · Yale J. Biol. Med. · 2007 · 80 · 51
45. 10.1073/pnas.131834511010.1073/pnas.1318345110 ↗
46. 10.1097/SHK.000000000000131210.1097/SHK.0000000000001312 ↗
47. 10.1186/s13018-020-01976-010.1186/s13018-020-01976-0 ↗
48. 10.1111/jocs.1455910.1111/jocs.14559 ↗
49. 10.1016/j.jhin.2021.02.01110.1016/j.jhin.2021.02.011 ↗
50. 10.1097/CPM.0b013e3182514f2910.1097/CPM.0b013e3182514f29 ↗
51. Mali A. · PharmaTutor · 2017 · 5 · 37
52. 10.1016/j.jconrel.2015.04.02710.1016/j.jconrel.2015.04.027 ↗
53. 10.1080/17476348.2017.126756810.1080/17476348.2017.1267568 ↗
54. Nysten P. H. · 1811
55. 10.1097/00000542-195103000-0000510.1097/00000542-195103000-00005 ↗
56. 10.1016/S0140-6736(00)97237-410.1016/S0140-6736(00)97237-4 ↗
57. 10.1097/00000658-194708000-0000610.1097/00000658-194708000-00006 ↗
58. 10.3346/jkms.1987.2.2.11110.3346/jkms.1987.2.2.111 ↗
59. 10.1378/chest.102.4.1175.10.1378/chest.102.4.1175. ↗
60. 10.3390/molecules2309221010.3390/molecules23092210 ↗
61. 10.3791/5146710.3791/51467 ↗
62. 10.1016/j.ijpharm.2014.11.02310.1016/j.ijpharm.2014.11.023 ↗
63. Lundgren C. E. G. · Undersea Hyperb. Med. · 2004 · 31 · 105
64. 10.1021/la102943210.1021/la1029432 ↗
65. 10.1016/j.colsurfa.2016.03.06410.1016/j.colsurfa.2016.03.064 ↗
66. 10.1126/scitranslmed.300367910.1126/scitranslmed.3003679 ↗
67. 10.1002/adhm.20120035010.1002/adhm.201200350 ↗
68. 10.1002/mrm.2296810.1002/mrm.22968 ↗
69. Pittman R. N. · 2011 · 3 · 1
70. 10.1111/micc.1201710.1111/micc.12017 ↗
71. 10.1007/s10877-012-9350-410.1007/s10877-012-9350-4 ↗
72. 10.1111/j.1582-4934.2011.01258.x10.1111/j.1582-4934.2011.01258.x ↗
73. 10.1016/B978-0-323-07307-3.10131-410.1016/B978-0-323-07307-3.10131-4 ↗
74. Ansari M. A. · Int. J. Res. · 2018 · 5 · 1230
75. 10.1002/jcp.2181210.1002/jcp.21812 ↗
76. 10.1039/C4LC00853G10.1039/C4LC00853G ↗
77. 10.3389/fphys.2017.0036510.3389/fphys.2017.00365 ↗
78. 10.1074/jbc.M30870320010.1074/jbc.M308703200 ↗
79. 10.1155/2013/63297210.1155/2013/632972 ↗
80. 10.1002/jcp.2169010.1002/jcp.21690 ↗
81. 10.1046/j.1523-1755.2001.00483.x10.1046/j.1523-1755.2001.00483.x ↗
82. 10.1056/NEJM19950309332100610.1056/NEJM199503093321006 ↗
83. 10.1113/jphysiol.2002.03799410.1113/jphysiol.2002.037994 ↗
84. 10.1177/095441191882303510.1177/0954411918823035 ↗
85. 10.1016/j.exer.2005.01.01810.1016/j.exer.2005.01.018 ↗
86. 10.1038/s41591-020-0868-610.1038/s41591-020-0868-6 ↗
87. 10.1038/nature0214510.1038/nature02145 ↗
88. 10.6026/9732063001621910.6026/97320630016219 ↗
89. 10.1016/j.nmni.2020.10073810.1016/j.nmni.2020.100738 ↗
90. 10.1016/S2213-2600(21)00218-610.1016/S2213-2600(21)00218-6 ↗
91. 10.1186/s12931-020-01462-510.1186/s12931-020-01462-5 ↗
92. 10.1113/jphysiol.2007.13888310.1113/jphysiol.2007.138883 ↗
93. 10.1164/rccm.202006-2157CP10.1164/rccm.202006-2157CP ↗
94. 10.1016/S1473-3099(20)30367-410.1016/S1473-3099(20)30367-4 ↗
95. 10.1183/13993003.01217-202010.1183/13993003.01217-2020 ↗
96. 10.1021/acs.accounts.8b0060610.1021/acs.accounts.8b00606 ↗
97. 10.1016/j.chemosphere.2011.05.05410.1016/j.chemosphere.2011.05.054 ↗
98. 10.1016/j.ultsonch.2018.05.03810.1016/j.ultsonch.2018.05.038 ↗
99. 10.1016/j.colsurfa.2010.03.00510.1016/j.colsurfa.2010.03.005 ↗
100. 10.1016/j.carbon.2017.12.05710.1016/j.carbon.2017.12.057 ↗